Tackling Eosinophilic Disorders
A Focus on Eosinophilic Granulomatosis with Polyangiitis and Hypereosinophilic Syndrome
Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis.
Emmi G., et al. Nat Rev Rheumatol. 2023;19(6):378-393.
The five-factor score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort.
Guillevin L, et al. Medicine. 2011;90(1):19-27.
Benralizumab as a steroid-sparing treatment option in eosinophilic granulomatosis with polyangiitis.
Gunter VP, et al. J Allergy Clin Immunol Pract. 2021;9(3):1186-1193.e1.
Real-world outcomes after anti–IL-5/anti–IL-5Rα treatment for hypereosinophilic syndrome: systematic literature review.
Jain P, Rowell J, Edmonds C, et al. J Allergy Clin Immunol: Global. 2026;5(1):100608.
HES and EGPA: two sides of the same coin.
Khoury P, Akuthota P, Kwon N, et al. Mayo Clin Proc. 2023;98(7):1054-1070.
Approach to the patient with suspected hypereosinophilic syndrome.
Klion, AD. Hematology Am Soc Hematol Educ Program. 2022;2022(1):47-54.
Benralizumab for patients with hypereosinophilic syndrome: a randomized, double-blind, placebo-controlled phase 3 trial (NATRON).
Ogbogu P, Roufosse F, Akuthota P, et al. Ann Allergy Asthma Immunol. 2025;135(5):S2-S3.
Efficacy and safety of mepolizumab in hypereosinophilic syndrome: a phase III, randomized, placebo-controlled trial.
Roufosse F, Kahn JE, Rothenberg ME, et al. J Allergy Clin Immunol. 2020;146(6):1397-1405.
World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management.
Shomali W, Gotlib J. Am J Hematol. 2022;97(1):129-148.
Red flags for clinical suspicion of eosinophilic granulomatosis with polyangiitis (EGPA).
Solans-Laqué R, Rúa-Figueroa I, Blanco Aparicio M, et al. Eur J Intern Med. 2024;128:45-52.
Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes.
Valent P, Klion AD, Roufosse F, et al. Allergy. 2023;78(1):47-59.
Eosinophilic granulomatosis with polyangiitis: latest findings and updated treatment recommendations.
Watanabe R and Hashimoto M. J Clin Med. 2023;12(18):5996.
Benralizumab versus mepolizumab for eosinophilic granulomatosis with polyangiitis.
Wechsler ME, et al. N Engl J Med. 2024;90(10):911-921.
Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis.
Wechsler ME, et al. N Engl J Med. 2017;376(20):1921-1932.
Two-year efficacy and safety of benralizumab in the treatment of eosinophilic granulomatosis with polyangiitis.
Wechsler ME, et al. Am J Respir Crit Care Med. 2025;211:A5029.
Clinical Practice Guidelines
2021 American College of Rheumatology (ACR)/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody– associated vasculitis.
Chung SA, et al. Arthritis Rheumatol. 2021;73(8):1366-1383.
2022 American College of Rheumatology/European Alliance of Associations for Rheumatology (EULAR) classification criteria for eosinophilic granulomatosis with polyangiitis.
Grayson PC, et al. Ann Rheum Dis. 2022;81(3):309-314.
EULAR recommendations for the management of ANCA- associated vasculitis: 2022 update.
Hellmich B, et al. Ann Rheum Dis. 2024;83(1):30-47.
Patient Advocacy Organizations and Resources
American College of Rheumatology (ACR)
ACR is a global medical society that serves physicians, health professionals, and scientists worldwide with the goal of advancing research and training to improve the health of people with rheumatic diseases.
American Lung Association
The American Lung Association’s mission is to save lives by improving lung health and preventing lung disease. We do this through education, advocacy, and research.
American Thoracic Society (ATS)
The mission of the ATS is to improve health worldwide by advancing research, clinical care, and public health in respiratory disease, critical illness, and sleep disorders.
European Alliance of Associations for Rheumatology (EULAR)
EULAR represents people with rheumatic and musculoskeletal diseases, health professionals in rheumatology, rheumatologists, researchers and scientific societies in the field of rheumatology of all the European nations.
Vasculitis Foundation
The mission of the Vasculitis Foundation is to build upon the collective strength of the vasculitis community, the Foundation supports, to inspire and empower individuals with vasculitis and their families through a wide range of education, research, clinical, and awareness initiatives.
